ArticleScientific reports2026
ACSL4 mediates ferroptosis to promote immunoglobulin A nephropathy progression: scRNA-seq analysis.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immunoglobulin A nephropathy (IgAN), the most prevalent primary glomerular disease, is a major cause of end-stage renal disease. Ferroptosis, a novel cell death mode induced by iron-dependent phospholipid peroxidation, has been implicated in the progression of chronic kidney disease. Whereas, Acyl-CoA synthetase long-chain family member 4 (ACSL4) is a key enzyme in pro-ferroptotic lipid metabolism that plays a critical role in ferroptosis. In this study, the role of ACSL4-mediated ferroptosis in IgAN progression was investigated by identifying the cell subset ACSL4+ Loop of Henle cells (LOHs) in IgAN via single-cell RNA sequencing (scRNA-seq). LOH cell populations were screened by dimensionality reduction with Uniform Manifold Approximation and Projection (UMAP), and ACSL4+ LOHs were annotated using cell marker genes. Gene Ontology and Kyoto Encyclopedia of Genes and Genomes (GO/KEGG) pathway enrichment analyses were performed based on marker genes of ACSL4+ LOHs. Cell-cell communication networks were established to infer interactions between ACSL4+ LOHs and other cell types. Pathological changes and LOH proportions in IgAN and normal kidney tissues were observed by hematoxylin and eosin (H&E) and Masson staining. Expression levels of ACSL4 in LOHs were determined by immunofluorescence to further investigate its effect on cell function. The proportion of LOHs was significantly elevated in the IgAN group compared to the Control group, and ACSL4 expression was significantly upregulated in LOHs. ACSL4+ LOHs were highly expressed in the IgAN group and enriched in the Ferroptosis pathway. Cellular communication between ACSL4+ LOHs and ECs, MEs, and PTCs was significantly enhanced in interleukin-6 (IL6) ligand-receptor pairs (IL6R+IL6ST). The proportion of LOHs was elevated, and ACSL4 expression was significantly increased in LOHs in the IgAN group. High expression of ACSL4+ LOHs, as revealed by scRNA-seq analysis, may enhance ferroptosis in IgAN and trigger inflammatory responses, thereby contributing to disease progression. This study is expected to provide insights into the mechanisms underlying the progression of IgAN.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.